Lntensive control of blood presure to reduce cardiovascular mortality and morbidity--comment on the 7th American JNC report and European treatment guidelines of hypertension
1Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA,2003, 289:2560-2572.
2Guidelines Committee. 2003 European Society of Hypertension -European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21:1011-1053.
31999 World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension. J Hypertens,1999,17:151-183.
4The sixth report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure.Arch Intern Med , 1997, 157:2413-2446.
5Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in The Framlngham Heart Study. Lancet, 2001, 358:1682-1686.
6Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in mlddle-aged women and men: The Framlngham Heart Study. JAMA, 2002,287 : 1003-1010.
7Lewington S, Clarke R, Qizilbash N, et al, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.Lancet,2002,360 : 1903-1913.
8Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension, 2002,40:920-927.
9Kottke TE, Stroebel RJ, Hoffman RS. JNC 7-It's more than high blood pressure. JAMA, 2003, 289:2573-2575.
4Johnson W,Nguyen ML,Patel R. Hypertension crisis in the emergency department[J]. Cardiol Clin,2012,30(4):533-43.
5Chobanian AV,Bakris GL,Black HR,et al. National Heart, Lung, and Blood Institute Joint National Committee on Preven- tion, Detection, Evaluation, and Treatment of High Blood Pres- sure National HighBlood Pressure Education Program Coor- dinatipg Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treat- ment of High Blood Pressure: the JNC 7 report[J]. JAMA,2013,289(19):2560-72.
6Susui S,Ohtsuka S,Ishiawa K,et al. Effects of nicardipine on coronary, vertebral and renal arterial flows in patients with essential hypertension[J]. Hypertens Res,2013,26(3):193-9.
7Cannon CM,Levy P,Baumann BM,et al. Intravenous nicardip ine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department :a subgroup analysis of the CLUE trial[J]. BMJ Open,2013,3(8):38-40.
8Fugit MD,Rubal BJ,Donovan DJ. Effects of intracoronary nicardipine,dihiazem and verapamil on coronary blood flow[J]. J Invasive Cardiol,2010,12(2):80-5.
9Kozaova M,Marco J,Heusch G,et al. The alphal adrenergic blocker urapidil imp roves contractile function in patients 3 months after coronary stenting: a randomized, double2blinded study[J]. Am Heart J,2014,147(2):6.
10Islas Weinstein L,Revueha A,Pando RH. Catecholamines and acetylcholine are key regulators of the interaction between microbes and the immune system[J]. Ann N Y Acad Sci,2015,1351(1):39-51.
